News | Cardiac Imaging | May 10, 2016

Study of 752 patients finds cardiac magnetic resonance better predicts risk at five year follow-up

cardiac magnetic resonance, CMR, SPECT, major adverse cardiovascular events, MACE predictor, Annals of Internal Medicine study

May 10, 2016 — Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT) at five years follow-up. The findings are published in Annals of Internal Medicine.

CMR is an MRI scan that focuses on the area around the heart. Unlike SPECT, CMR does not involve ionizing radiation and the large CE-MARC (Clinical Evaluation of Magnetic Resonance imaging in Coronary heart disease) study demonstrated that CMR had high diagnostic accuracy, with higher sensitivity and negative predictive value compared with SPECT.

However, data on the prognostic value of CMR remain limited. A predefined objective of CE-MARC was to assess the ability of CMR and SPECT to predict MACE at five-year follow-up. To do so, researchers studied 752 patients from the CE-MARC study who were being investigated for suspected coronary heart disease. The patients were scheduled to undergo CMR and SPECT in random order, followed by X-ray coronary angiography (the reference standard) within four weeks. The investigators followed up with patients every year for five years to assess for MACE.

The researchers found that at five-year follow-up, CMR was a stronger predictor of risk for MACE than SPECT, independent of clinical cardiovascular risk factors, angiography result or initial patient treatment. The researchers conclude that CMR should be considered a robust alternative to SPECT for the diagnosis and management of patients with suspected coronary heart disease.

For more information: www.annals.org


Related Content

News | Cardiac Imaging

May 20, 2025 — Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter ...

Time May 27, 2025
arrow
News | Pediatric Imaging

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric ...

Time May 20, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
Subscribe Now